論文

査読有り
2018年6月1日

Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases

Drug Discovery Today
  • Masaaki Waragai
  • ,
  • Gilbert Ho
  • ,
  • Yoshiki Takamatsu
  • ,
  • Yuka Shimizu
  • ,
  • Hiromu Sugino
  • ,
  • Shuei Sugama
  • ,
  • Takato Takenouchi
  • ,
  • Eliezer Masliah
  • ,
  • Makoto Hashimoto

23
6
開始ページ
1305
終了ページ
1311
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.drudis.2018.05.009
出版者・発行元
Elsevier Ltd

Given the paradigm of anti-insulin resistance in therapies for metabolic syndrome, there has been considerable interest in adiponectin (APN), an adipocyte-derived sensitizer of insulin receptor signaling. In contrast to hypoadiponectinemia in metabolic syndrome, evidence suggests that Alzheimer's disease (AD) and other diseases, including chronic heart failure (CHF) and chronic kidney disease (CKD), are characterized by hyperadiponectinemia as well as the APN/obesity paradoxes, indicating that a decrease in APN might also be beneficial for these diseases. Thus, distinct from metabolic syndrome, it is anticipated that APN receptor antagonists rather than agonists might be effective in therapy for some chronic diseases.

リンク情報
DOI
https://doi.org/10.1016/j.drudis.2018.05.009
ID情報
  • DOI : 10.1016/j.drudis.2018.05.009
  • ISSN : 1878-5832
  • ISSN : 1359-6446
  • SCOPUS ID : 85047187801

エクスポート
BibTeX RIS